-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
IASLC President Discusses Accomplishments, Adjustments, and The Year Ahead
Dr. Tetsuya Mitsudomi joined the Board of Directors of IASLC in 2011 and has served as its board president since 2019. IASLC awarded Dr. Mitsudomi its Mary J. Matthews Pathology/Translational Research Award in 2013 for a lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Mitsudomi, professor in the Division of Thoracic Surgery…
-
Finding the Benefits of the Virtual World: A Conversation with Dr. Heather Wakelee
Heather Wakelee, MD, is the President-Elect of the IASLC and will assume presidential responsibilities at the 2021 WCLC in September. She is the Chief of the Division of Oncology at Stanford University and Deputy Director of the Stanford Cancer Institute. She is also the principal investigator of numerous clinical trials and lead investigator for the…
-
Interim Chief Scientific Officer Dr. Giorgio Scagliotti Brings Vast IASLC Knowledge to Role
With a long history in leadership positions at the IASLC, Dr. Scagliotti is fully prepared to help guide the society’s scientific projects through a transition period. Dr. Scagliotti, is professor of medical oncology at the University of Turin School of Medicine, Italy, where he is also a member of the administrative board. He is also…
-
Prof. Caroline Dive Honored with Mary J. Matthews Pathology/Translational Research Award for Work with CTCs
Caroline Dive, CBE, PhD, FBPhS, FMedSci, Director of the CRUK Manchester Institute Cancer Biomarker Centre, University of Manchester, has been recognized by the IASLC with the Mary J. Matthews Pathology/Translational Research Award. The award recognizes an IASLC scientist for a lifetime achievement in pathology and translational research of thoracic malignancies. “I am utterly delighted and…
-
Dr. Pan-Chyr Yang Honored by IASLC for Contributions to Lung Cancer Prevention
Pan-Chyr Yang, MD, PhD, Chair Professor at the National Taiwan University Hospital and Academician of Academia Sinica, Taiwan, will be recognized by the International Association for the Study of Lung Cancer (IASLC) with the Joseph W. Cullen Prevention/Early Detection Award at the fully virtual IASLC 2020 World Conference on Lung Cancer (WCLC). This award recognizes…
-
Paul A. Bunn, Jr., Scientific Award to Dr. Joan H. Schiller
Breath is life. We depend so much on our ability to breathe with ease but, for patients with lung cancer, that is no small task. For her entire career, Joan H. Schiller, MD, FASCO helped patients breathe easier and enjoy a better quality of life. Dr. Schiller has helped to break the taboo of talking…
-
Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials
By now, investigators, sponsors, clinicians, and patients are widely aware of the crisis facing cancer clinical trials. With scientific discoveries occurring more rapidly than ever, there is a growing need to bring novel therapies to patients as efficiently as possible. Yet, in the United States, fewer than 3% of adults with cancer enroll in clinical…
-
Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC
Tissue still represents the “gold standard” biosource for molecular profiling of lung cancer. However, the use of tissue samples in clinical practice is associated with several technical and biological limitations. For instance, tissue specimens can provide only a small picture of the complex molecular landscape of patients with lung cancer, freezing the situation at the…
-
Lung Cancer Screening in Poland Pilot Program Is Restarted After COVID-19 Lockdown
Discussions about lung cancer screening in Poland started in 2006, and between 2008 and 2010 four lung cancer screening programs were independently implemented by thoracic surgeons in Szczecin, Gdańsk, Poznań, and Warsaw, each with separate funding. From that point until 2018, more than 50,000 individuals at high risk of developing lung cancer were examined through…
-
FDA’s Project Patient Voice Launched to Provide Data on PROs
In 2020 the U.S. Food and Drug Administration (FDA) launched Project Patient Voice, an online platform for patients and caregivers along with their health care providers to look at patient-reported symptom data from cancer clinical trials. This new website, how it functions, and how it might be improved was discussed in July at the FDA-ASCO…
View ILCN Archives
Provider Resources
Popular Articles